EGFR and neoplasm: While the presence of classical activating mutations is a strong predictor of favorable tumor response to EGFR tyrosine kinase inhibitors, rare EGFR mutations, such as the exon 20 insertion mutation, are heterogeneous, largely resistant to first- and second-generation drugs, and the efficacy of third-generation osimertinib is limited.